{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T04:56:31Z","timestamp":1767848191492,"version":"3.49.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"51","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.vaccine.2020.10.067","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T15:17:55Z","timestamp":1604589475000},"page":"8206-8215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Assessing the cost-utility of preferentially administering Heplisav-B vaccine to certain populations"],"prefix":"10.1016","volume":"38","author":[{"given":"Elizabeth M.","family":"Rosenthal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric W.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eli S.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noele P.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Schillie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2020.10.067_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6701a1","article-title":"Prevention of hepatitis B virus infection in the United States: recommendations of the advisory committee on immunization practices","volume":"67","author":"Schillie","year":"2018","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2020.10.067_b0010","unstructured":"Centers for Disease C. Recommendation of the Immunization Practices Advisory Committee (ACIP). Inactivated hepatitis B virus vaccine. MMWR Morbidity and mortality weekly report. 1982;31:317-22, 27-8."},{"issue":"15","key":"10.1016\/j.vaccine.2020.10.067_b0015","doi-asserted-by":"crossref","first-page":"455","DOI":"10.15585\/mmwr.mm6715a5","article-title":"Recommendations of the advisory committee on immunization practices for use of a hepatitis B vaccine with a novel adjuvant","volume":"67","author":"Schillie","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2020.10.067_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0749-3797(98)00003-8","article-title":"Immunogenicity of Hepatitis B vaccines","volume":"15","author":"Averhoff","year":"1998","journal-title":"Am J Prev Med"},{"issue":"1","key":"10.1016\/j.vaccine.2020.10.067_b0025","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-14-820","article-title":"Factors associated with hepatitis B vaccine series completion in a randomized trial for injection drug users reached through syringe exchange programs in three US cities","volume":"14","author":"Bowman","year":"2014","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2020.10.067_b0030","doi-asserted-by":"crossref","unstructured":"Drachman R, Isacsohn M, Rudensky B, Drukker A. Vaccination against hepatitis B in children and adolescent patients on dialysis. Nephrol Dial Transplant 1989;4:372\u20134.","DOI":"10.1093\/oxfordjournals.ndt.a091892"},{"issue":"5","key":"10.1016\/j.vaccine.2020.10.067_b0035","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0264-410X(89)90157-6","article-title":"Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination","volume":"7","author":"Shaw","year":"1989","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.vaccine.2020.10.067_b0040","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/j.vaccine.2012.01.087","volume":"30","author":"Halperin","year":"2012","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2020.10.067_b0045","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.vaccine.2017.12.038","article-title":"Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults","volume":"36","author":"Jackson","year":"2018","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2020.10.067_b0050","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.4161\/hv.24256","article-title":"Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine","volume":"9","author":"Halperin","year":"2013","journal-title":"Human Vacc Immunotherap"},{"issue":"46","key":"10.1016\/j.vaccine.2020.10.067_b0055","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1016\/j.vaccine.2013.05.068","article-title":"Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40\u201370 years of age","volume":"31","author":"Heyward","year":"2013","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2020.10.067_b0060","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.vaccine.2014.12.060","article-title":"Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus","volume":"33","author":"Janssen","year":"2015","journal-title":"Vaccine"},{"issue":"31","key":"10.1016\/j.vaccine.2020.10.067_b0065","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1016\/j.vaccine.2015.05.070","article-title":"Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18\u201370 years of age","volume":"33","author":"Janssen","year":"2015","journal-title":"Vaccine"},{"issue":"46","key":"10.1016\/j.vaccine.2020.10.067_b0070","doi-asserted-by":"crossref","first-page":"5306","DOI":"10.1016\/j.vaccine.2013.05.067","article-title":"Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease","volume":"31","author":"Janssen","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.10.067_b0075","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1016\/j.vaccine.2013.05.014","article-title":"Cost-effectiveness of hepatitis B vaccination using HEPLISAV in selected adult populations compared to Engerix-B(R) vaccine","volume":"31","author":"Kuan","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.10.067_b0080","unstructured":"Centers for Disease Control and Prevention. CDC Vaccine Price List. 2019."},{"key":"10.1016\/j.vaccine.2020.10.067_b0085","unstructured":"Centers for Disease Control and Prevention. Unpublished data; 2019."},{"key":"10.1016\/j.vaccine.2020.10.067_b0090","doi-asserted-by":"crossref","unstructured":"Chahal HS, Peters MG, Harris AM, McCabe D, Volberding P, Kahn JG. Cost-effectiveness of Hepatitis B Virus Infection Screening and Treatment or Vaccination in 6 High-risk Populations in the United States. Open Forum Infectious Diseases 2018;6.","DOI":"10.1093\/ofid\/ofy353"},{"issue":"9","key":"10.1016\/j.vaccine.2020.10.067_b0095","doi-asserted-by":"crossref","first-page":"673","DOI":"10.7326\/M15-0547","article-title":"Incident Hepatitis B Virus Infection in HIV-Infected and HIV-Uninfected Men Who Have Sex With Men From Pre-HAART to HAART Periods: A Cohort Study","volume":"163","author":"Falade-Nwulia","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2020.10.067_b0100","series-title":"Hepatitis B Epidemiology and Prevention of Vaccine-Preventable Diseases","author":"Centers for Disease Control and Prevention","year":"2015"},{"issue":"S2","key":"10.1016\/j.vaccine.2020.10.067_b0105","doi-asserted-by":"crossref","first-page":"S389","DOI":"10.2105\/AJPH.2008.151332","article-title":"Compliance With Multiple-Dose Vaccine Schedules Among Older Children, Adolescents, and Adults: Results From a Vaccine Safety Datalink Study","volume":"99","author":"Nelson","year":"2009","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2020.10.067_b0110","unstructured":"Centers for Disease Control and Prevention. Viral Hepatitis Surveillance, United States, 2016. Division of Viral Hepatitis; 2017."},{"issue":"3","key":"10.1016\/j.vaccine.2020.10.067_b0115","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2105\/AJPH.2013.301601","article-title":"Estimating Acute Viral Hepatitis Infections From Nationally Reported Cases","volume":"104","author":"Klevens","year":"2014","journal-title":"Am J Public Health"},{"issue":"4","key":"10.1016\/j.vaccine.2020.10.067_b0120","doi-asserted-by":"crossref","first-page":"245","DOI":"10.7326\/M17-1689","article-title":"Low Prevalence of Hepatitis B Vaccination Among Patients Receiving Medical Care for HIV Infection in the United States, 2009 to 2012","volume":"168","author":"Weiser","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2020.10.067_b0125","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.4161\/hv.7.12.18333","article-title":"Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults >\/=50 years","volume":"7","author":"Gilbert","year":"2011","journal-title":"Human vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2020.10.067_b0130","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2337\/dc12-0759","article-title":"Cost-Effectiveness of Hepatitis B Vaccination in Adults With Diagnosed Diabetes","volume":"36","author":"Hoerger","year":"2013","journal-title":"Diabetes Care"},{"issue":"31-32","key":"10.1016\/j.vaccine.2020.10.067_b0135","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1016\/S0264-410X(02)00397-3","article-title":"The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population","volume":"20","author":"Jacques","year":"2002","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2020.10.067_b0140","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.vaccine.2011.10.084","article-title":"Effect of age and frequency of injections on immune response to hepatitis B vaccination in drug users","volume":"30","author":"Tran","year":"2012","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2020.10.067_b0145","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1080\/21645515.2016.1164362","article-title":"Prospective clinical trial of hepatitis B vaccination in adults with and without type-2 diabetes mellitus","volume":"12","author":"Van Der Meeren","year":"2016","journal-title":"Human Vacc Immunotherap"},{"issue":"24","key":"10.1016\/j.vaccine.2020.10.067_b0150","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1016\/j.vaccine.2012.03.018","article-title":"Assessing the immunological response to hepatitis B vaccination in HIV-infected patients in clinical practice","volume":"30","author":"Mena","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.10.067_b0155","unstructured":"Bureau of Labor Statistics (BLS). Consumer Price Index for All Urban Consumers (CPI-U): US city average, by expenditure category, January 2019. 2019."},{"key":"10.1016\/j.vaccine.2020.10.067_b0160","unstructured":"Bureau of Labor Statistics (BLS). Current Employment Statistics. 2019."},{"issue":"1","key":"10.1016\/j.vaccine.2020.10.067_b0165","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/bmb\/ldq033","article-title":"Health outcomes in economic evaluation: the QALY and utilities","volume":"96","author":"Whitehead","year":"2010","journal-title":"Br Med Bull"},{"issue":"8","key":"10.1016\/j.vaccine.2020.10.067_b0170","doi-asserted-by":"crossref","first-page":"589","DOI":"10.7326\/M15-0420","article-title":"Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis","volume":"163","author":"Kim","year":"2015","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.vaccine.2020.10.067_b0175","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.2337\/dc12-0312","article-title":"Immune Response of Hepatitis B Vaccine Among Persons With Diabetes: A systematic review of the literature","volume":"35","author":"Schillie","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.vaccine.2020.10.067_b0180","unstructured":"Hung M, Williams WW, Lu P, Kim DK, Grohskopf LA, Pilishvili T, et al. Vaccination Coverage Among Adults in the United States, National Health Interview Survey, 2016. Centers for Disease Control and Prevention; 2018."},{"key":"10.1016\/j.vaccine.2020.10.067_b0185","unstructured":"Centers for Disease Control and Prevention. Viral Hepatitis Surveillance, United States, 2017. Division of Viral Hepatitis; 2019."},{"key":"10.1016\/j.vaccine.2020.10.067_b0190","doi-asserted-by":"crossref","unstructured":"Harris AM, Iqbal K, Schillie S, Britton J, Kainer MA, Tressler S, et al. Increases in Acute Hepatitis B Virus Infections - Kentucky, Tennessee, and West Virginia, 2006-2013. MMWR Morbidity and mortality weekly report. 2016;65:47-50.","DOI":"10.15585\/mmwr.mm6503a2"},{"key":"10.1016\/j.vaccine.2020.10.067_b0195","doi-asserted-by":"crossref","unstructured":"Maxwell JC. The prescription drug epidemic in the United States: a perfect storm. Drug Alcohol Rev. 2011;30:264-70.","DOI":"10.1111\/j.1465-3362.2011.00291.x"},{"issue":"2","key":"10.1016\/j.vaccine.2020.10.067_b0200","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2105\/AJPH.2017.304132","article-title":"Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014","volume":"108","author":"Zibbell","year":"2018","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2020.10.067_b0205","first-page":"453","article-title":"Increases in hepatitis C virus infection related to injection drug use among persons aged <\/=30 years - Kentucky, Tennessee, Virginia, and West Virginia, 2006\u20132012","volume":"64","author":"Zibbell","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"35","key":"10.1016\/j.vaccine.2020.10.067_b0210","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1016\/j.vaccine.2019.05.089","article-title":"Challenges with hepatitis B vaccination of high risk adults \u2013 A pilot program","volume":"37","author":"Bridges","year":"2019","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2020.10.067_b0215","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa1515195","article-title":"HIV Infection Linked to Injection Use of Oxymorphone in Indiana, 2014\u20132015","volume":"375","author":"Peters","year":"2016","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1016\/j.vaccine.2021.07.070","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000}}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20313876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20313876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T23:25:01Z","timestamp":1616714701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20313876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":43,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0264410X20313876"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.10.067","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.vaccine.2021.07.070","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing the cost-utility of preferentially administering Heplisav-B vaccine to certain populations","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.10.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}